Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
Applied Genetic Technologies (AGTC) Reiterated at Buy by Stifel, ACHMB3 Progress is Encouraging
-
Mirati Therapeutics (MRTX) PT Lowered to $150 at Stifel, Following Weak Amgen's Lumakras Data, AMGN's Lower Estimate Will Dominate Sentiment
-
Incyte (INCY) Reiterated at Buy by Truist, Dip is a Buying Opportunity, Opzelura Launch is Key Highlight
-
Amgen's (AMGN) Initial Guidance Looks Favorable, Reiterate Market Perform - BMO Capital
-
Incyte (INCY) Reiterated at Market Perform by BMO Capital, 2022 All About Opzelura Revenues
-
Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report
-
Pfizer (PFE) Reiterated at Overweight by Cantor Fitzgerald, "Confident PFE Can Meet its Guidance for a 5-year Revenue CAGR of at least 6%"
-
Sangamo BioSciences (SGMO) Reiterated at Hold by Stifel, New Data Not Thesis Changing, Looking For Successful ERT Withdrawal Going Forward
-
No Significant Impact on Intercept (ICPT) from France Withdrawal, Focus Remains on Future Data - H. C. Wainwright
-
Regeneron (REGN) PT Lowered to $728 at Truist Securities, Competitive Pressure on Praluent and Eylea Cited
-
Editas Medicine's (EDIT) CMO Departure Likely to Weigh In on Investor Sentiment in Near Term, Reiterate Hold - Stifel
-
Truist Securities Reiterates Buy Rating on Catalyst Pharmaceutical (CPRX) on Prelim Q4 Results
-
Cowen Reiterates Outperform Rating on Evelo Biosciences Inc (EVLO) on Latest EDP1815 Data
-
Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital
-
2022 Product Launches Will Provide Good Foundation for Bristol-Myers Squibb's (BMY) Future Growth, Reiterate Outperform - BMO Capital
-
Positively Inclined for Potential Approval of Aeglea's (AGLE) pegzilarginase BLA - Needham & Company
-
Truist Securities Reiterates Buy Rating, $95 PT on Merck (MRK) Following Earnings
-
NHS Announcement Paves Way for Orchard's (ORTX) Revenue Generation in England and Wales, but Focus Remains on BLA Submission - Stifel
-
Increasing Comfort That NuCana's (NCNA) Phase 3 Data Will Perform to Expectations, Shares Are Compelling - Oppenheimer
-
Conviction in Marinus's (MRNS) Phase 3 RAISE Data Remains High, MRNS is One of Top Picks for 2022, EU Delay Should Not Impact US Timeline - Truist
-
Intellia's (NTLA) Acquisition of Rewrite is Intriguing, Expands and Differentiates NTLA from Competitors - Stifel
-
FDA Resubmission is Positive for Lipocine (LPCN), Underscores Good Execution, Reiterate Overweight - Cantor Fitzgerald
-
Rewrite Acquisition is Highly Positive for Intellia Therapeutics (NTLA), Continues to Position NTLA as Leader in Genome Editing - Truist Securities
-
Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets
-
All Focus on Athersys' (ATHX) Upcoming Readout from Pivotal TREASURE Study, May Strongly Drive Shares - Needham & Company
-
BMO Capital Reiterates Market Perform Rating on Merck (MRK) Following Earnings
-
Cantor Fitzgerald Reiterates Merck (MRK) at Overweight on Earnings, Pipeline and Growth "Remains Underappreciated"
-
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
-
Oppenheimer Reiterates PDS Biotechnology (PDSB) at Outperform, "Broader Market Recovery Could be Particularly Supportive" for the Stock
-
Gilead Sciences (GILD) PT Lowered to $75 at Truist Securities
-
BMO Capital Lowers PT on Gilead (GILD) to $75 Following Earnings, Reiterates Focus on TROPiCS-02 Data Readout
-
BMO Capital Lowers PT on Gilead (GILD) to $75 Following Earnings, Reiterates Focus on TROPiCS-02 Data Readout
-
Phase 2b/3 PRISM Upcoming Data is Trevi's (TRVI) Most Important Readout, Maintain Buy Into the Analysis - Needham & Company
-
Arcutis (ARQT) Seborrheic Dermatitis Opportunity is Underappreciated, Represents a Free Call Option on Stock - Mizuho
-
Neurocrine Biosciences (NBIX) Earnings Preview by Needham: Focus on Ingrezza Growth and Pipeline
-
Phase 3 Results Are Encouraging and De-Risk Madrigal (MDGL) Shares, resmetirom Likely to Be First Drug Approved for NASH and Liver Fibrosis - H. C. Wainwright
-
Neurocrine Biosciences (NBIX), Intra-Cellular Therapies (ITCI), and Biohaven Pharmaceutical (BHVN) Are Top Potential Acquisition Targets for Biogen (BIIB) - Mizuho Investor Survey
-
Early Vaccine Approval Allows Moderna (MRNA) to Take Extra Market Share, May Drive Increased Pricing and Additional $2B-$5B in Sales - Cowen
-
Sierra's (SRRA) momelotinib Peak Sales Projected at $1.7B - H. C. Wainwright
-
Nippon Deal is Transformational for Capricor (CAPR), Provides Significant Validation for CAP-1002 - H. C. Wainwright
-
Nurix (NRIX) Reiterated at Buy at Needham & Company, "Expect Value Creation in 2022 Across Nurix Pipeline"
-
Biogen's (BIIB) Samsung Sale Frees Up Capital for Strategic Alternatives, Expect Uptick in Stock - Stifel
-
Iovanace Biotherapeutics (IOVA) Upgraded to Buy at Stifel, FDA Hire Likely to Help Resolve Assay Potency Issue
-
Taysha Gene's (TSHA) Biomarker Data Trending in Right Direction, Safety Concerns Likely to Resolve - Truist
-
Moderna (MRNA) Price Target Lowered to $200 at Cowen, Analyst Cites Development Risks of Flu, RSV and CMV Programs
-
Facility Sale is a Creative Way to Strengthen Balance Sheet, Move is a Positive for Atara Biotherapeutics (ATRA) PT Raised to $25 - Stifel
-
Cantor Fitzgerald Reiterates Overweight on Eli Lilly (LLY) Despite Medicare Coverage Risks, Still Sees Clear Path for Coverage Contingent on Successful Phase 3
-
Vertex (VRTX) is a Clean Revenue Growth Story, Pipeline is Discounted and Stock Remains Preferred - BMO Capital
-
Business Update Support Positive Thesis on Evolus (EOLS), Guidance Looks Conservative, Reiterate Overweight - Cantor Fitzgerald
-
Checkpoint's (CKPT) cosibelimab Data Checks Right Boxes and Provides Further Validation of Potential - Cantor Fitzgerald
